Corona Remedies Limited has completed the mandatory newspaper publication of its unaudited financial results for the third quarter and nine months ended December 31, 2025, in compliance with regulatory requirements.

Board Approval and Publication Details

The Board of Directors of Corona Remedies Limited approved the unaudited financial results (both standalone and consolidated) at their meeting held on Monday, February 02, 2026. The results cover the performance for the third quarter and nine months ended December 31, 2025.

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the financial results advertisement in Financial Express in both English and Gujarati editions on February 03, 2026.

Regulatory Compliance and Accessibility

The extract of the newspaper publication has been made available on the company's website at www.coronaremedies.com for stakeholder access. This ensures broader accessibility of the financial information beyond the newspaper publication.

Stock Exchange Communication

Corona Remedies Limited has formally communicated the newspaper publication to both major stock exchanges where its shares are listed:

• BSE Limited: Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai (Scrip Code: 544644)
• National Stock Exchange of India Limited: Exchange Plaza, Bandra Kurla Complex, Mumbai (Symbol: CORONA)

The communication was signed by Chetna Dharajiya, Company Secretary and Compliance Officer, ensuring proper authorization and compliance with corporate governance norms.

Document Availability

The complete financial results, along with the limited review report by M/s. Deloitte Haskins & Sells LLP (the company's statutory auditors), are accessible through multiple channels:

• Company website: www.coronaremedies.com
• BSE website: www.bseindia.com
• NSE website: www.nseindia.com
• Quick Response (QR) code provided in the publication

This multi-channel approach ensures comprehensive stakeholder access to the financial information, supporting transparency and regulatory compliance in the pharmaceutical sector.

CORONA Remedies Limited has announced its third quarter financial results for fiscal year 2026, following the board meeting held on February 02, 2026. The pharmaceutical company delivered strong operational performance with significant EBITDA growth and margin expansion, despite mixed results in revenue growth and net profitability.

Strong EBITDA Performance

The company demonstrated robust operational efficiency with EBITDA reaching ₹840M compared to ₹690M in the corresponding quarter last year. The EBITDA margin also showed improvement, expanding to 24.56% from 23.15% in the previous year, indicating enhanced operational leverage and cost management.

Financial Performance Overview

The company's comprehensive financial results show contrasting trends across different performance metrics. While operational efficiency improved significantly, the overall financial performance presented a mixed picture during the reporting period.

Revenue Growth and Profitability Analysis

CORONA Remedies achieved significant revenue expansion during the quarter, with total income reaching ₹3.4B compared to ₹2.97B in the corresponding period last year. However, despite strong revenue performance and improved EBITDA margins, the company's standalone net profit declined to ₹413M from ₹448M recorded in the same quarter of the previous fiscal year.

Board Meeting and Regulatory Compliance

The results were formally approved during the Board of Directors meeting held on February 02, 2026. The meeting addressed the unaudited financial results for both standalone and consolidated operations, covering the third quarter and nine months ended December 31, 2025, in compliance with SEBI regulations.